The implications of colorectal cancer molecular biology in clinical practice.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Surgical Oncology Clinics of North America

• Publication date

  2008-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.soc.2007.12.005PMID 18375356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Molecular Imaging as a Tool for Personalized and Targeted Anticancer Therapy

  2007cited by this paper
• Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy

  2006cited by this paper
• Biology of colorectal liver metastases: A review

  2006cited by this paper
• From gut homeostasis to cancer.

  2006cited by this paper
• Colorectal cancer: genetics of development and metastasis

  2006cited by this paper
• Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas

  2006cited by this paper
• Novel approaches to treatment of advanced colorectal cancer with anti‐EGFR monoclonal antibodies

  2006cited by this paper
• Microsatellite instability in colorectal cancer

  2006cited by this paper
• Molecular biology of colorectal cancer: new targets.

  2006cited by this paper
• Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions

  2006cited by this paper
• Imaging colorectal cancer.

  2006cited by this paper
• Clinical observation: Beau's lines on fingernails after deep saturation dives.

  2006cited by this paper
• Control of colorectal metastasis formation by K-Ras.

  2005cited by this paper
• Molecular imaging of antiangiogenic agents.

  2005cited by this paper
• Antibody-based therapies for colorectal cancer.

  2005cited by this paper
• A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis.

  2005cited by this paper
• First Amsterdam, then Bethesda, now Melbourne?

  2005cited by this paper
• The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma

  2005cited by this paper
• Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas

  2005cited by this paper
• Molecular imaging: what can be used today

  2005cited by this paper
• A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines

  2004cited by this paper
• APC Genotype Is Not a Prognostic Factor in Familial Adenomatous Polyposis Patients With Colorectal Cancer

  2004cited by this paper
• Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Systematic review of genetic influences on the prognosis of colorectal cancer

  2004cited by this paper
• Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.

  2004cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Targeted therapy and pharmacogenomic programs

  2003cited by this paper
• Microsatellite instability in colon cancer.

  2003cited by this paper
• Implications of Genetic Testing in the Management of Colorectal Cancer

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Molecular prognostics in colorectal cancer.

  2003cited by this paper
• The molecular and genetic basis of colon cancer.

  2002cited by this paper
• Genetic and epigenetic alterations in colon cancer.

  2002cited by this paper
• Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery.

  2002cited by this paper
• Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

  2001cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer

  2001cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001cited by this paper
• Genetic pathways in the evolution of morphologically distinct colorectal neoplasms.

  2001cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• Molecular imaging: an overview.

  2001cited by this paper
• Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed.

  2000cited by this paper
• Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

  2000cited by this paper
• Linking colorectal cancer to Wnt signaling.

  2000cited by this paper
• Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

  2000cited by this paper
• Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer

  2000cited by this paper
• Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes’ C colon cancer

  2000cited by this paper
• Tumor suppressor p53: regulation and function.

  2000cited by this paper
• Wnt signaling and cancer.

  2000cited by this paper
• Activation of c-K-ras mutations in human gastrointestinal tumors.

  2000cited by this paper
• Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.

  2000cited by this paper
• Molecular stool screening for colorectal cancer

  2000cited by this paper
• Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

  2000cited by this paper
• Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways.

  2000cited by this paper
• p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.

  2000cited by this paper
• The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer.

  2000cited by this paper
• Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor

  1999cited by this paper
• Adjuvant therapy of colon cancer

  1999cited by this paper
• Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

  1999cited by this paper
• Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

  1999cited by this paper
• Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers

  1999cited by this paper
• Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2

  1999cited by this paper
• Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.

  1999cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

  1998cited by this paper
• High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.

  1998cited by this paper
• Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer.

  1998cited by this paper
• Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.

  1998cited by this paper
• Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

  1998cited by this paper
• Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

  1998cited by this paper
• Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.

  1998cited by this paper
• Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer

  1998cited by this paper
• Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

  1998cited by this paper
• p53 alterations are associated with improved prognosis in distal colonic carcinomas.

  1997cited by this paper
• Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer.

  1997cited by this paper
• Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

  1997cited by this paper
• Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.

  1997cited by this paper
• Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer.

  1996cited by this paper
• Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.

  1996cited by this paper
• Detection of DCC and Ki‐ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence

  1996cited by this paper
• Better survival rates in patients with MLH1-associated hereditary colorectal cancer.

  1996cited by this paper
• MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma

  1996cited by this paper
• Lessons from Hereditary Review Colorectal Cancer

  1996cited by this paper
• DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1

  1996cited by this paper
• The DCC protein and prognosis in colorectal cancer.

  1996cited by this paper
• Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

  1995cited by this paper
• Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon.

  1995cited by this paper
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper
• Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

  1994cited by this paper
• Epidemiology of colorectal adenomas.

  1994cited by this paper
• Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.

  1994cited by this paper
• The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival

  1994cited by this paper
• The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer

  1993cited by this paper
• Microsatellite instability in cancer of the proximal colon.

  1993cited by this paper
• Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

  1993cited by this paper

• Estudio proteómico en pacientes con metástasis hepáticas de cáncer colo-rectal. Identificación de diferentes perfiles proteómicos en relación a los criterios clínico patológicos convencionales de gravedad

  2017cites this paper
• Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases.

  2017cites this paper
• Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study

  2013cites this paper
• Prognostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin in Metastatic and Nonmetastatic Colorectal Cancer

  2013cites this paper
• Genetic aspects of colorectal cancer and its impact on disease management

  2013cites this paper
• Serum Neutrophil Gelatinase-Associated Lipocalin in Patients with Colorectal Liver Metastases: Preliminary Results of An Exploratory Prospective Study

  2010cites this paper
• Current Opinion in Oncology. Current world literature.

  2009cites this paper
• Induction of genomic instability in cultured human colon epithelial cells following exposure to isocyanates

  2009cites this paper
• Genome stability depends on the accurate regulation of cellular responses to DNA damage and on the integrity of DNA repair systems . Cells use many DNA damage checkpoint pathways to maintain both cell viability and genomic stability

  year unknowncites this paper